Engineered for half-life: fatty-acid side chain + residue substitutions.
Part of the Metabolic & GLP-1 peptides cluster
Overview
Semaglutide is a modified GLP-1 receptor agonist peptide designed for extended half-life. It is an approved prescription medicine in many jurisdictions and a major case study in peptide engineering.
Source & context
Biological / chemical source: Synthetic (modified)
Primary research or clinical context: Approved for type 2 diabetes & weight management (prescription)
Engineering highlights
Key design choices include substitution for DPP-4 resistance and a C18 fatty diacid side chain that enables albumin binding and once-weekly dosing in approved products.
Educational note
Discussions of semaglutide on this site are educational. Use of prescription medicines should follow licensed medical guidance only.
Sequence
One-letter sequence commonly cited for Semaglutide (educational; isoforms and modifications may differ):
FAQ about Semaglutide
What is Semaglutide?+
Semaglutide is a modified GLP-1 receptor agonist peptide designed for extended half-life. It is an approved prescription medicine in many jurisdictions and a major case study in peptide engineering.
Is Semaglutide an approved medicine?+
Semaglutide: Approved for type 2 diabetes & weight management (prescription). Always follow licensed medical guidance for approved products.
What is the typical length of Semaglutide?+
Semaglutide is commonly described as approximately 31 amino acids (Incretin analog).